104508-22-7

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 3-(bromomethyl)-, methyl ester is used as a chemical intermediate for the synthesis of various drugs, especially antihypertensive drugs, due to its unique chemical structure and reactivity.
Used in Organic Synthesis:
Benzeneacetic acid, 3-(bromomethyl)-, methyl ester is used as a reagent in organic synthesis, enabling the creation of a wide range of chemical products through its versatile chemical properties.
Used in Research and Development:
Benzeneacetic acid, 3-(bromomethyl)-, methyl ester is utilized as a solvent in research and development, facilitating various experimental procedures and chemical reactions in the laboratory setting.

Upstream product

• 621-36-3 m-methylphenylacetic acid 
• 53088-69-0 methyl 3-methylphenylacetate 
• 67-56-1 methanol 
• 118647-53-3 (3-bromomethyl-phenyl)-acetic acid 

Downstream Products

• 141879-56-3 ethyl N-(diphenylmethylene)-3-<(carbomethoxy)methyl>-DL-phenylalaninate 
• 677775-69-8 2-butylamino-9-(3-methoxycarbonylmethylbenzyl)adenine 
• 132691-37-3 3-azidomethylphenyl acetic acid methyl ester 
• 930777-87-0 methyl 3-{[N-(2-hydroxyethyl)-N-methyl]aminomethyl}phenylacetate 
• 677775-71-2 2-chloro-9-(3-methoxycarbonylmethylbenzyl)adenine 
• 677775-67-6 9-(3-methoxycarbonylmethylbenzyl)-2-(2-methoxyethoxy)adenine 
• 149492-32-0 3-hydroxymethylphenylacetic acid 
• 1439400-24-4 C₁₁H₁₄O₂S 
• 1439400-06-2 C₁₄H₁₆N₂O₂ 
• 1439400-26-6 C₁₀H₁₂O₄S 
• 1439400-25-5 C₁₁H₁₄O₄S 
• 1439395-34-2 C₃₃H₃₉N₇O₄S 
• 1439400-20-0 C₁₅H₂₁NO₄ 
• 1439400-19-7 C₁₆H₂₃NO₄ 

Relevant academic research and scientific papers

IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS

Compounds of formula (I) and salts thereof: wherein R1, R2, R3, a, X1, X2, X3, X4, and X5 are as defined hereinbefore. Compounds of formula (I) and salts thereof have been found to inhibit the binding of the BET family of bromodomain containing proteins to, for example, acetylated lysine residues and thus may have use in therapy, for example in the treatment of autoimmune and inflammatory diseases, such as rheumatoid arthritis; and cancers.

Synthesis and complexing properties of cyclic benzylopeptoids-a new family of extended macrocyclic peptoids

An efficient protocol for the solid-phase synthesis of six members of a new class of extended macrocyclic peptoids (based on ortho-, meta- and para-N-(methoxyethyl)aminomethyl phenylacetyl units) is described. Theoretical (DFT) and experimental (NMR) studies on the free and Na+-complexed cyclic trimers (3-5) and tetramers (6-8) demonstrate that annulation of the rigidified peptoids can generate new hosts with the ability to sequestrate one or two sodium cations with the affinities and stoichiometries defined by the macrocycle morphology. Ion transport studies have been also performed in order to better appreciate the factors promoting transmembrane cation translocation.

HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

HETEROCYCLIC INHIBITORS OF GLUTAMINASE

The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases using the heterocyclic compounds of the invention.

Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept

Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC50 50 nM) and rapidly metabolized by human plasma (T1/2 2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.

METHOD FOR PRODUCING ADENINE COMPOUND

A method for producing adenine compound (1): , wherein m and n are independently an integer of 2 to 5, R1 is C1-6 alkyl group, R2 and R3 are the same or different, and hydrogen atom, or C1-6 alkyl group, or R2 and R3 are combined with the adjacent nitrogen atom to form pyrrolidine, morpholine, piperidine, piperazine, etc., and R4 is C1-3 alkyl group, which comprises a step of reacting compound (2): and compound (3): in the presence of a boron-containing reducing agent.

NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE

The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

6-Membered heterocyclic compound and use thereof

A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH2 and the like; RO1 to RO4 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U1—(RW1)(RW2)—U2—U3 group (U1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; RW1 and RW2 represent hydrogen atom and the like; U2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoma, ulcerative colitis and the like.

SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted dihydropyridines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.

Hydroxyquinolone derivatives compounds which have pharmaceutical utility

This present invention relates to a class of 4-hydroxy-2-(1H)-quinolones which are substituted in the 3-position by an optionally substituted aryl substituent. These compounds are selective non-competitive antagonists of N-methyl-D-aspartate (NMDA) receptors.